Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial

Purpose Investigate safety and tolerability of adrecizumab, a humanized monoclonal adrenomedullin antibody, in septic shock patients with high adrenomedullin. Methods Phase-2a, double-blind, randomized, placebo-controlled biomarker-guided trial with a single infusion of adrecizumab (2 or 4 mg/kg b.w...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Intensive care medicine 2021-11, Vol.47 (11), p.1284-1294
Hauptverfasser:	Laterre, Pierre-François, Pickkers, Peter, Marx, Gernot, Wittebole, Xavier, Meziani, Ferhat, Dugernier, Thierry, Huberlant, Vincent, Schuerholz, Tobias, François, Bruno, Lascarrou, Jean-Baptiste, Beishuizen, Albertus, Oueslati, Haikel, Contou, Damien, Hoiting, Oscar, Lacherade, Jean-Claude, Chousterman, Benjamin, Pottecher, Julien, Bauer, Michael, Godet, Thomas, Karakas, Mahir, Helms, Julie, Bergmann, Andreas, Zimmermann, Jens, Richter, Kathleen, Hartmann, Oliver, Pars, Melanie, Mebazaa, Alexandre
Format:	Artikel
Sprache:	eng
Schlagworte:	Adrenomedullin Adverse events Anesthesiology Antibodies Antibodies, Monoclonal, Humanized - therapeutic use Belgium Biomarkers Clinical trials Comparative analysis Confidence intervals Critical Care Medicine Double-Blind Method Emergency Medicine Ethylenediaminetetraacetic acid France General & Internal Medicine Germany Health aspects Hemodynamics Humans Infection Intensive Intensive care Life Sciences Life Sciences & Biomedicine Medicine Medicine & Public Health Mortality NCT NCT03085758 Original Pain Medicine Patients Pediatrics Pharmaceutical sciences Placebos Pneumology/Respiratory System Randomization Rankings Safety Science & Technology Sepsis Septic shock Shock, Septic - drug therapy Treatment Outcome Viral antibodies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Purpose Investigate safety and tolerability of adrecizumab, a humanized monoclonal adrenomedullin antibody, in septic shock patients with high adrenomedullin. Methods Phase-2a, double-blind, randomized, placebo-controlled biomarker-guided trial with a single infusion of adrecizumab (2 or 4 mg/kg b.w.) compared to placebo. Patients with adrenomedullin above 70 pg/mL,
ISSN:	0342-4642 1432-1238
DOI:	10.1007/s00134-021-06537-5